Expert Interview
Discussing the poster presented at ESCO 2025 "Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours"
Ticker(s): CRBP, GMABInstitution: Florida Cancer Specialists
- Medical Oncologist and Director of Drug Development at Florida Cancer Specialists.
- Specializes in experimental therapeutics for head, neck and thoracic medical oncology.
- Previously served as an Associate Professor of Medicine at the University of Miami where he was a leader for Phase 1 oncology clinical research as well as the Head and Neck Group.
how are you currently managing HSNCC?
Added By: wilson_adminthoughts on peto + pembro?
Added By: wilson_adminview on CRB-701?
Added By: wilson_adminDo you think that CRB-701 will have a material advantage treating H&N tumors which are HPV positive (compared to tumors HPV negative)? Will the upcoming stratification data at ASCO in CRB-701 in monotherapy treatment of H&N shed light on this potential advantage in expected CRB-701 plus pembro combo data expected in Q4 2026 ?
Added By: stevengoldmanAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
